UroGen Pharma Ltd.
URGN
$9.66
-$0.01-0.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -58.46% | 29.13% | -3.46% | -24.10% | -18.91% |
| Total Depreciation and Amortization | 15.04% | 1.14% | -25.07% | -17.22% | 2.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 50.89% | -19.47% | 67.26% | -21.07% | -12.26% |
| Change in Net Operating Assets | 261.85% | -447.43% | 173.38% | -149.70% | 585.82% |
| Cash from Operations | 50.77% | -16.49% | 25.17% | -144.19% | 24.87% |
| Capital Expenditure | -19.79% | -14.29% | -- | -- | 44.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 156.95% | -982.75% | -10.62% | 219.76% | -2,353.09% |
| Cash from Investing | 156.79% | -989.73% | -11.24% | 219.16% | -2,928.93% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.53% | -81.48% | 49.38% | 136,542.50% | -99.94% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | -- | -- | -100.00% |
| Cash from Financing | -99.82% | -60.51% | 83.48% | 136,542.50% | -99.97% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 149.65% | -207.09% | 142.96% | 249.96% | -124.50% |